What is it about?
Direct antiviral agents locally manufactured in Egypt at very affordable price to Egyptian patients with chronic hepatitis C could be used for mass treatment in Egypt with great efficacy in terms of sustained viral response as well as good tolerability.
Featured Image
Why is it important?
This study is very impressive in our community reflecting the importance of generic daclatasvir/sofosbuvir in treating and reducing the prevalence of HCV infection in Egypt.
Perspectives
We have been treating a huge number of Egyptian patient with chronic hepatitis C using these medication. The long term outcome of patients with sustained virologic response is persuaded. We expect these beneficial effects impact positively in terms of reducing the disease burden significantly in our country
Professor Monkez M Yousif
Zagazig University
Read the Original
This page is a summary of: Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt, Alimentary Pharmacology & Therapeutics, November 2017, Wiley,
DOI: 10.1111/apt.14428.
You can read the full text:
Contributors
The following have contributed to this page
